After allogeneic stem cell transplant, severe grade III-IV gastrointestinal (GI) acute GvHD is associated with significant morbidity and mortality, and generally results in poor outcomes. Salvage therapy for patients who fail steroid therapy is not well defined in the literature. In the current retrospective study, we reviewed our experience with the combination of basiliximab and infliximab in 21 patients with severe, grade III-IV GI acute GvHD of whom 16 met the definition for steroid-refractory disease. The overall response rate was 76%, with 43% CR at a median time of 21 days after beginning treatment. The survival at 1 year was 24%, with most deaths due to complications from GvHD and recurrence of primary disease. All five of the long-term survivors have chronic GvHD. On the basis of a review of the literature, this regimen does not seem to be significantly more effective than other strategies for severe GI GvHD and seems to be worse than the results reported for basiliximab alone. Future studies of single-agent basiliximab and newer agents are required.
INTRODUCTION
Grade III-IV acute GvHD remains an intractable problem after allogeneic hematopoietic stem cell transplant with no approved therapies beyond steroids and little demonstrable progress in the last two decades. [1] [2] [3] In addition to the high mortality often related to infection, there is considerable morbidity with associated compromise in quality of life and high financial costs. These issues are heightened in patients with severe gastrointestinal (GI) involvement, where prolonged hospitalization due to highvolume diarrhea and malabsorption is common. Further, as recent studies show that liver GvHD is markedly decreasing in frequency 4 and skin GvHD seems more responsive to treatment, 2 severe GI GvHD represents an urgent unmet need often leading to death.
On the basis of encouraging results reported in a small number of patients with steroid-refractory GvHD treated with daclizumab alone or combined with infliximab, 5 we adopted the daclizumab plus infliximab regimen as our standard practice for severe GI GvHD and then converted to basiliximab plus infliximab when daclizumab became unavailable in 2009. We report our results in 21 consecutively treated patients who developed acute grade III-IV GvHD with severe GI involvement (16 meeting the definition of steroid refractory) following matched related, matched unrelated, mismatched related or mismatched unrelated allogeneic stem cell transplantation. To our knowledge, this is the first report of the combination of basiliximab plus infliximab for the treatment of severe GI GvHD.
MATERIALS AND METHODS

Study design
Patient population. All patients at least 18 years of age with grade III-IV GvHD with severe GI involvement who were treated with basiliximab plus infliximab between January 2009 and October 2014 were included. Patients with late-onset acute GI GvHD developing more than 100 days from transplant that occurred in the setting of immunosuppression taper and with no clinical manifestations of chronic GvHD were also included in this analysis. With the exception of one patient, initial treatment of GvHD with steroid therapy consisted of methylprednisolone (MP) 2 mg/kg divided into two daily doses. One patient received a 4-day pulse of highdose MP before transitioning to MP 2 mg/kg divided into two daily doses.
Treatment. Monoclonal Ab (MAB) treatment consisted of basiliximab 20 mg IV on days 1 and 4 and infliximab 10 mg/kg IV weekly × 4 doses. Basiliximab and infliximab were administered sequentially on day 1 of the regimen. Patients could be retreated with basiliximab and/or infliximab because of recurrent or persistent disease. Patients continued tacrolimus and 17 of 20 patients either continued or started mycophenolate mofetil around the time that MAB was initiated. As described by Srinivasan et al., 5 there was an attempt to taper steroids once MAB was initiated but this was carried out at the discretion of the treating physician and was generally performed at weekly intervals in responding patients. All patients received at least two doses of basiliximab and two weekly doses of infliximab.
Clinical grading of acute GvHD before and after MAB administration was defined according to the Glucksberg grading criteria. [6] [7] [8] Steroid-refractory GvHD was defined as progression within 3 days or no improvement after 5-7 days of MP 1-2 mg/kg per day. 9 All patients received antifungal prophylaxis with voriconazole with the initiation of steroid therapy and underwent weekly blood cultures and surveillance PCR studies for CMV.
The primary objective was to evaluate response and survival for patients treated with MAB therapy. Complete response (CR) was defined as resolution of all clinical signs of acute GvHD and normalization of hepatic transaminases. Partial response (PR) was defined as reduction of acute GvHD by at least one grade in one target organ (specifically the GI tract) without progression in another target organ. No response was defined as lack of improvement or worsening of acute GvHD in at least one organ. Response and survival were calculated from the first day of MAB therapy until the last day of follow-up or death. Pertinent data points related to the GvHD index episode were collected and included dose and duration of steroid therapy, time from transplant to initiation of steroid treatment, time to response and additional therapies used following treatment with MAB therapy. The algorithm of Copelan et al. 10 was used to assign the primary cause of death.
The study was designed as a quality improvement analysis of our practice by a retrospective chart review and approved by Yale University's Institutional Review Board (IRB).
RESULTS
Patient characteristics
Between January 2009 and October 2014, 240 patients who received allogeneic stem cell transplant were evaluated. Of these, 21 patients received MAB therapy for stages III-IV GvHD with severe GI involvement. Baseline characteristics are summarized in Table 1 . Median age was 57 (range 20-71). The most common indication for transplant was acute leukemia. All patients underwent allogeneic transplant with bone marrow (n = 3) or peripheral blood (PBSC; n = 18), with stem cell sources from matched related (n = 7), matched unrelated (n = 10), mismatched related (n = 1) or mismatched unrelated (n = 3) donors. Most patients received pretransplant conditioning with reduced-intensity regimens (n = 13), and received primary GvHD prophylaxis with tacrolimus and mycophenolate mofetil (n = 18).
GvHD and treatment
Median time between stem cell infusion and start of steroid therapy was 43 days for early acute GvHD (n = 11) and 255 days (n = 10) for late-onset acute GvHD. In most cases, late-onset acute GvHD occurred during immunosuppression taper and in one case after donor lymphocyte infusion. Overall grade of acute GvHD as defined by the Glucksberg grading scale at the time of initiation of steroid therapy was grade III (n = 13; 62%) or grade IV (n = 8; 38%) as detailed in Table 2 . Sites of involvement included the GI tract alone (n = 9), GI tract and skin (n = 11), and GI tract and liver (n = 1). Patients were treated with MP ⩾ 2 mg/kg per day for a median of 5 days (range 1-23) before initiation of MAB therapy. Eight patients began MAB before completing 5 days of steroid therapy of whom three patients had worsening disease at day 4. A total of 13 patients began MAB therapy after 5 or more days of steroids, including three patients who began MAB therapy beyond a 7-day steroid trial because of a period of initial improvement followed by worsening GvHD. Therefore, 16 of 21 patients met the definition of steroid-refractory GI GvHD. Median numbers of basiliximab and infliximab doses were 2 (range, 2-8) and 4 (range, 2-13), respectively. Overall, 9 (43%) patients achieved a CR at a median of 21 days (range, 2-82) and 7 (33%) achieved a PR at a median of 34 days (range, 16-43). Five patients had no response (Table 3) .
One patient in CR received two additional doses of basiliximab for recurrence that subsequently returned to remission and three patients in PR received a total of four, six and eight total doses of basiliximab. A second CR patient received an extra dose of infliximab for unclear reasons and four patients in PR received 5, 8, 9 and 13 total doses of infliximab (three of the four PR patients received extra doses of both MAB). None of the non-responding patients received extra doses of either MAB. Another CR patient had recurrence of GvHD that responded to a brief increase in steroids without further MAB treatment. Seven patients in CR (including the patient who received an extra dose of infliximab) did not have GvHD recurrence. Five of seven patients with PR had recurrence or progression of GvHD and none achieved a CR with additional MAB therapy.
With respect to steroid taper, five of nine CR patients were able to at least temporarily taper off steroids (restarted for the development of chronic GvHD), whereas only one of seven PR patients was able to be fully tapered off steroids.
The median survival was 161 days for CR patients, 348 days for PR and 132 days for no response. Excluding four patients whose primary cause of death was recurrence of their primary disease, the median survival of CR patients was 1036 days. Overall survival at 1 year from the start of MAB therapy was 24%; five patients remain alive at a median follow-up of 1036 days (range, 781-1709) including three of nine (33%) CR and two of seven (28%) PR. There appeared to be a better survival in patients who achieved a CR after treatment for early onset acute versus late-onset GvHD but the numbers are too small to be conclusive (Table 4) . Salvage treatment regimens initiated in the partial and non-responders included sirolimus (n = 2), cyclophosphamide (n = 1), tocilizumab (n = 2), ustekinumab (n = 1) and denileukin diftitox (n = 1).
The primary cause of death among the 16 responders included GvHD in seven patients and disease recurrence in four patients. In patients whose primary cause of death was GvHD, infections were a contributing cause of death in four ( Table 2 ). All the five surviving patients developed chronic GvHD, including two with eye involvement and three with extensive skin disease.
DISCUSSION
Although steroids remain first-line therapy for the treatment of acute GvHD, response rates in patients with grade III-IV disease are poor, with no apparent improvement in survival over the past 15 years. 2 Severe GI disease is even less responsive and is associated with significant morbidity and mortality. Overall acute GvHD grade, a n (%) 
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Treatment options beyond steroid therapy remain poorly defined and currently there is no standard second-line therapy for steroidrefractory acute GvHD. The use of combination therapies that block activated T cells (daclizumab/basiliximab) and a pivotal cytokine (TNF-α) in GI GvHD (infliximab), therefore represents an attractive strategy and is supported by the results of small studies in which patients responded to the combination of daclizumab plus infliximab. 5, 13 As a result, we adopted the daclizumab/ infliximab regimen as our standard treatment for severe GI GvHD and then converted to basiliximab and infliximab when daclizumab became unavailable.
In the present study, 21 patients with grade III-IV GvHD with severe GI involvement and treated with the combination of basiliximab plus infliximab were evaluated for response and survival. An overall response rate of 76% with 43% CR was achieved; however, only 24% of patients were alive at 1 year. Although the response and outcomes appeared to be better than those achieved with daclizumab and infliximab reported by Rager et al., 14 we cannot exclude differences in patient selection as the patients in the two studies differed in stem cell source, conditioning regimens and GvHD prophylaxis.
Importantly, the survival results in the current study do not appear to be better than those reported by Jamani et al.,
2 who observed a 30% 1-year survival in a patient population similar to ours. They also noted that a high initial response rate did not translate into a survival benefit and did not find a better survival in the steroid-responsive patients. These observations underscore the need for better therapy in this group of patients and also suggest that more promising agents should not necessarily be reserved pending a 5-7-day steroid trial as even a response to the latter does not obviate the need for additional therapy in patients with severe disease.
In fact, in some recent studies for the treatment of grade II-IV GvHD, experimental agents have been started with steroids at the time of diagnosis of GvHD. A phase II trial showed that mycophenolate mofetil was better than etanercept, pentostatin and denileukin diftitox when each agent was combined with steroids; 15 however, a phase III trial did not confirm that mycophenolate mofetil plus steroids was superior to steroids alone. 16 Similarly, a phase III study that compared steroids plus daclizumab versus steroids alone was stopped because of inferiority of the daclizumab arm. 17 The negative results for daclizumab and denileukin diftitox have not supported an important therapeutic role for IL2 receptor blockade with those agents and have even raised concerns that CD25 inhibition may increase risk of GvHD because of decreased regulatory T cells, which also signal through CD25. Abbreviations: B/I = basiliximab/infliximab; CoNS = coagulase negative Staphylococcus; CR = complete response; CNS = central nervous system; DAH = diffuse alveolar hemorrhage; DLI = donor lymphocyte infusion; ESRD = end-stage renal disease; MUD = match-unrelated donor; MRD = match-related donor; MRSA = methicillin-resistant Staphylococcus aureus; NA = not applicable; NR = no response; PR = partial response; VRE = vancomycin-resistant Enterococcus. Similarly, the inferior results of the etanercept arm in the four-arm phase II trial have diminished enthusiasm for the benefit of TNF-α inhibition. 15 The studies by Rager et al. 14 of daclizumab plus infliximab as well as the current study do not support a major role for combined IL2 receptor and TNF-α antagonism with existing agents.
Although basiliximab has an identical mechanism of action to daclizumab and appears equivalent to the latter in the treatment and prophylaxis of renal rejection, 18 the reported results for basiliximab in steroid-refractory GvHD patients have been surprisingly encouraging (Table 5) . [19] [20] [21] Three series including 104 patients demonstrate an overall response rate of 71-87% and survival was 53% at 16 months in the largest trial by Wang et al.
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It is not clear why our results with basiliximab in combination with infliximab appear to be worse or at least no better than basiliximab alone. One possible reason for the better outcomes of basiliximab alone compared with basiliximab plus infliximab might be less global immunosuppression with the former program. However, this is only likely to be established by a randomized trial. Of note, although in the current study an attempt was made to reduce steroids once MAB therapy was initiated, the appropriate rapidity and extent of the steroid taper remain unanswered questions.
Major limitations of the current study include the retrospective non-randomized study design as well as a mixture of pretransplant diagnoses, conditioning regimens and degree of HLA matching. However, like some other studies of severe GvHD, a high response rate to basiliximab plus infliximab did not translate into a significant survival benefit, stressing the importance of prolonged follow-up in this group of patients. Although an ongoing prospective trial is testing the basiliximab/infliximab combination in steroid-refractory GvHD (NCT01485055), future studies need to confirm the single-agent activity and survival impact of basiliximab alone. In addition, it seems likely that better strategies and agents are required for substantive improvement in patients with severe GI GvHD.
